RT Journal Article
T1 Clinical and hematological follow-Up of long-termoral therapy with type-I interferon in cats naturallyinfected with feline Leukemia virus or felineiImmunodeficiency Virus
A1 Gómez-Lucía Duato, María Esperanza
A1 Collado Alcalá, Victorio Manuel
A1 Miró  Corrales, Guadalupe
A1 Martín Iniesta, Sonsoles
A1 Benítez Rico, Laura
A1 Doménech, Ana
AB Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV), two of the most important pathogens of cats, produce chronic systemic diseases with progressive death of cells involved in the immune response, ultimately leading to death. Immunostimulants is one of the few alternatives to the symptomatic treatment. In this study, 27 naturally FeLV-infected (FeLV+) and 31 naturally FIV-infected (FIV+) cats were administered orally by their owners 60 IU/day of recombinant human interferon alpha (rHuIFN-α) for four months in alternate weeks. Clinical status was evaluated and blood samples collected at four different visits or months (M): pretreatment (M0), mid-treatment (M2), end of treatment (M4), and 4–8 months after end of treatment (M10). Most cats ostensibly improved their clinical status, and many became asymptomatic. rHuIFN-α treatment improved the anemic processes observed at M0 (at least in cats with mild or moderate anemia) and leukocyte counts, including a more favorable CD4+/CD8+ ratio. An increase in the serum gammaglobulin concentration was seen in 80% of the cats. Despite observing an obvious favorable progress in the clinical, biopathological, and CD4+/CD8+ values during treatment, almost invariably all the parameters analyzed worsened after treatment discontinuation (M10), which suggests that the interferon-α protocol should be either extended or include additional cycles for a long-lasting benefit in FeLV+ and FIV+ cats.
PB MDPI
SN Electronic: 2076-2615
YR 2020
FD 2020-08-20
LK https://hdl.handle.net/20.500.14352/7868
UL https://hdl.handle.net/20.500.14352/7868
LA eng
NO Ministerio de Ciencia e Innovación (MICINN)
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 27 abr 2024